Neuraxpharm Buys Into Cannabidiol Business
Acquires Switzerland’s STU, Specializing In CBD Consumer Products
Neuraxpharm has entered the cannabidiol arena by striking a deal to buy Switzerland’s STU, a developer and distributor of natural cannabidiol consumer products.
You may also be interested in...
Neuraxpharm says a deal with Takeda to acquire the only buccal midazolam approved across Europe, Buccolam, not only gives the CNS specialist a strong asset but also offers the opportunity to expand its commercial footprint into the Nordics and Ireland.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.
Neuraxpharm has struck a deal to acquire Glenmark’s CNS portfolio in Poland. As part of the agreement, Glenmark’s Jacek Sawicki has been named as general manager of Neuraxpharm Polska and will lead a business that now incorporates Glenmark’s CNS commercial team.